Manuel Fernández Martínez
Research Subjects
Manuel Fernández Martínez has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Marian Martínez De Pancorboa
BIOMICs Research Group, University of the Basque Country EHU, 01006 Vitoria-Gasteiz, Spain
4 shared publications - Juan J. Zarranz
Unidad de Disautonomía, Servicio y Cátedra de Neurología, Hospital de Cruces, Barakaldo, Bizkaia, Universidad del País Vasco, Spain
3 shared publications - Alberto Bergareche
Neuroscience Unit, Biodonostia Research Institute, San Sebastian, Spain; Department of Neurology, University Hospital Donostia, San Sebastian, Spain
2 shared publications Ana Molano Salazar
Movement Disorders and Autonomic Unit, Department of Neurology, Cruces University Hospital, Department of Neurosciences, University of the Basque Country, Spain
2 shared publications- Antonio Lobo
Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain
2 shared publications - Covadonga Fernández-Maiztegui2 shared publications
Latest Publications
- 1 February 2016
- Published by Elsevier in Medicina Clinica
- Vol. 146 (3) , 141
Linfomatosis meníngea como recidiva tardía de macroglobulinemia de Waldenström
- 1 February 2016
- Published by Elsevier in Medicina Clinica
- Vol. 146 (3) , 141
Linfomatosis meníngea como recidiva tardía de macroglobulinemia de Waldenström
- 1 May 2015
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 21 (5) , 494-499
Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene
- 1 May 2015
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 21 (5) , 494-499
Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene
- 16 July 2014
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 41 (3) , 887-901
Cognitive and Neuroimaging Profiles in Mild Cognitive Impairment and Alzheimer's Disease: Data from the Spanish Multicenter Normative Studies (NEURONORMA Project)
The aim of this study was to characterize the neuropsychological and neuroimaging profiles of mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients, and to study the magnitude of the differences by comparing both outcomes with healthy subjects in a cross-sectional manner. Five hundred and thirty-five subjects (356 cognitively normal adults (CONT), 79 MCI, and 100 AD) were assessed with the NEURONORMA neuropsychological battery. Thirty CONT, 23 MCI, and 23 AD subjects from this sample were included in the neuroimaging substudy. Patients' raw cognitive scores were converted to age and education-adjusted scaled ones (range 2-18) using co-normed reference values. Medians were plotted to examine the cognitive profile. MRIs were processed by means of FreeSurfer. Effect size indices (Cohen's d) were calculated in order to compare the standardized differences between patients and healthy subjects. Graphically, the observed cognitive profiles for MCI and AD groups produced near to parallel lines. Verbal and visual memories were the most impaired domains in both groups, followed by executive functions and linguistic/semantic ones. The largest effect size between AD and cognitively normal subjects was found for the FCSRT (d = 4.05, AD versus CONT), which doubled the value obtained by the best MRI measure, the right hippocampus (d = 1.65, AD versus CONT). Our results support the notion of a continuum in cognitive profile between MCI and AD. Neuropsychological outcomes, in particular the FCSRT, are better than neuroimaging ones at detecting differences among subjects.
- 16 July 2014
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 41 (3) , 887-901
Cognitive and Neuroimaging Profiles in Mild Cognitive Impairment and Alzheimer's Disease: Data from the Spanish Multicenter Normative Studies (NEURONORMA Project)
The aim of this study was to characterize the neuropsychological and neuroimaging profiles of mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients, and to study the magnitude of the differences by comparing both outcomes with healthy subjects in a cross-sectional manner. Five hundred and thirty-five subjects (356 cognitively normal adults (CONT), 79 MCI, and 100 AD) were assessed with the NEURONORMA neuropsychological battery. Thirty CONT, 23 MCI, and 23 AD subjects from this sample were included in the neuroimaging substudy. Patients' raw cognitive scores were converted to age and education-adjusted scaled ones (range 2-18) using co-normed reference values. Medians were plotted to examine the cognitive profile. MRIs were processed by means of FreeSurfer. Effect size indices (Cohen's d) were calculated in order to compare the standardized differences between patients and healthy subjects. Graphically, the observed cognitive profiles for MCI and AD groups produced near to parallel lines. Verbal and visual memories were the most impaired domains in both groups, followed by executive functions and linguistic/semantic ones. The largest effect size between AD and cognitively normal subjects was found for the FCSRT (d = 4.05, AD versus CONT), which doubled the value obtained by the best MRI measure, the right hippocampus (d = 1.65, AD versus CONT). Our results support the notion of a continuum in cognitive profile between MCI and AD. Neuropsychological outcomes, in particular the FCSRT, are better than neuroimaging ones at detecting differences among subjects.
- Open Access
Oestrogen receptor polymorphisms are an associated risk factor for mild cognitive impairment and Alzheimer disease in women APOE ɛ4 carriers: a case–control study
Objectives: Examine the role of single nucleotide polymorphisms (SNPs) in the oestrogen receptor (ER) genes: rs9340799, rs2234693, rs2228480 (in theESR1gene) and rs4986938 (in theESR2gene) as a risk factor for amnesic mild cognitive impairment (MCIa) and Alzheimer's disease (AD) and its possible association with the apolipoprotein E (APOE)gene.Design: We have investigated the independent and combined association of different alleles of the oestrogen receptor genes and APOE*ɛ4 allele with cognitive impairment using a case–control design.Setting: Participants were prospectively recruited from the neurology departments of several Basque Country hospitals.Participants: This study comprised 816 Caucasian participants who were aged 50 years and older: 204 MCIa, 350 sporadic patients with AD and 262 healthy controls.Primary and secondary outcome measures: Clinical criteria and neuropsychological tests were used to establish the diagnostic groups (MCIa, AD and healthy controls). A dichotomous variable was used for each allele and genotype and the association with MCIa and AD was established using Logistic Regression Models.Results: Neither alleles nor genotypes of SNPs rs9340799, rs2234693, rs2228480 and rs4986938 of oestrogen receptor genes (ESR1andESR2) are independently associated with the risk of MCIa or AD. However, the genetic profile created with the combination of the less represented alleles of these SNPs (expressed as XPAA) was associated with an increased risk for MCIa (OR=3.30, 95% CI 1.28 to 8.54, p=0.014) and AD (OR=5.16, 95% CI 2.19 to 12.14, pESR1andESR2SNPs are associated with an increased risk for MCIa and AD in women APOEɛ4 allele carriers.
Open AccessOestrogen receptor polymorphisms are an associated risk factor for mild cognitive impairment and Alzheimer disease in women APOE ɛ4 carriers: a case–control study
Objectives: Examine the role of single nucleotide polymorphisms (SNPs) in the oestrogen receptor (ER) genes: rs9340799, rs2234693, rs2228480 (in theESR1gene) and rs4986938 (in theESR2gene) as a risk factor for amnesic mild cognitive impairment (MCIa) and Alzheimer's disease (AD) and its possible association with the apolipoprotein E (APOE)gene.Design: We have investigated the independent and combined association of different alleles of the oestrogen receptor genes and APOE*ɛ4 allele with cognitive impairment using a case–control design.Setting: Participants were prospectively recruited from the neurology departments of several Basque Country hospitals.Participants: This study comprised 816 Caucasian participants who were aged 50 years and older: 204 MCIa, 350 sporadic patients with AD and 262 healthy controls.Primary and secondary outcome measures: Clinical criteria and neuropsychological tests were used to establish the diagnostic groups (MCIa, AD and healthy controls). A dichotomous variable was used for each allele and genotype and the association with MCIa and AD was established using Logistic Regression Models.Results: Neither alleles nor genotypes of SNPs rs9340799, rs2234693, rs2228480 and rs4986938 of oestrogen receptor genes (ESR1andESR2) are independently associated with the risk of MCIa or AD. However, the genetic profile created with the combination of the less represented alleles of these SNPs (expressed as XPAA) was associated with an increased risk for MCIa (OR=3.30, 95% CI 1.28 to 8.54, p=0.014) and AD (OR=5.16, 95% CI 2.19 to 12.14, pESR1andESR2SNPs are associated with an increased risk for MCIa and AD in women APOEɛ4 allele carriers.
- 22 March 2011
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 123 (5) , 316-324
Prevalence and European comparison of dementia in a ≥75-year-old composite population in Spain
Virués‐Ortega J, de Pedro‐Cuesta J, Vega S, Seijo‐Martínez M, Saz P, Rodríguez F, Rodríguez‐Laso Á, Reñé R, de las Heras SP, Mateos R, Martínez‐Martín P, Mahillo‐Fernández I, López‐Pousa S, Lobo A, Reglà JL, Gascón J, García FJ, Fernández‐Martínez M, Boix R, Bermejo‐Pareja F, Bergareche A, Sánchez‐Sánchez F, de Arce A, del Barrio JL; On behalf of the Spanish Epidemiological Studies on Ageing Group. Prevalence and European comparison of dementia in a ≥75‐year‐old composite population in Spain. Acta Neurol Scand: 2011: 123: 316–324. © 2010 John Wiley & Sons A/S. Objectives – To estimate dementia prevalence in Spain. Materials and methods – Nine probabilistic and geographically defined samples participated. A screening design based on the MMSE was implemented. Positively screened individuals underwent clinical evaluation. The total number of cases in Spain was estimated. Prevalence was confronted to that of other European countries. Results – Five hundred and forty‐six persons aged ≥75 participated, 49 had dementia (35 with Alzheimer’s disease [AD], 10 with vascular dementia [VD], 4 other; 25 first diagnosed in the study). Age‐ and sex‐adjusted prevalence and estimated nationwide cases were 7.5% (95% CI 5.4–9.7), 5.6 (95% CI 3.7–7.5) and 1.4 (95% CI 0.5–2.3), and 290,000 (95% CI 208,000–372,000), 214,000 (95% CI 141,000–288,000) and 54,000 (95% CI 20,000–88,000) for dementia, AD and VD, respectively. Conclusions – Dementia prevalence in Spain is comparable to other European populations, while a high number of undiagnosed cases live in the community. The potential impact of Mediterranean diet, hypertension control and decreasing vascular risk factors is discussed.
- 22 March 2011
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 123 (5) , 316-324
Prevalence and European comparison of dementia in a ≥75-year-old composite population in Spain
Virués‐Ortega J, de Pedro‐Cuesta J, Vega S, Seijo‐Martínez M, Saz P, Rodríguez F, Rodríguez‐Laso Á, Reñé R, de las Heras SP, Mateos R, Martínez‐Martín P, Mahillo‐Fernández I, López‐Pousa S, Lobo A, Reglà JL, Gascón J, García FJ, Fernández‐Martínez M, Boix R, Bermejo‐Pareja F, Bergareche A, Sánchez‐Sánchez F, de Arce A, del Barrio JL; On behalf of the Spanish Epidemiological Studies on Ageing Group. Prevalence and European comparison of dementia in a ≥75‐year‐old composite population in Spain. Acta Neurol Scand: 2011: 123: 316–324. © 2010 John Wiley & Sons A/S. Objectives – To estimate dementia prevalence in Spain. Materials and methods – Nine probabilistic and geographically defined samples participated. A screening design based on the MMSE was implemented. Positively screened individuals underwent clinical evaluation. The total number of cases in Spain was estimated. Prevalence was confronted to that of other European countries. Results – Five hundred and forty‐six persons aged ≥75 participated, 49 had dementia (35 with Alzheimer’s disease [AD], 10 with vascular dementia [VD], 4 other; 25 first diagnosed in the study). Age‐ and sex‐adjusted prevalence and estimated nationwide cases were 7.5% (95% CI 5.4–9.7), 5.6 (95% CI 3.7–7.5) and 1.4 (95% CI 0.5–2.3), and 290,000 (95% CI 208,000–372,000), 214,000 (95% CI 141,000–288,000) and 54,000 (95% CI 20,000–88,000) for dementia, AD and VD, respectively. Conclusions – Dementia prevalence in Spain is comparable to other European populations, while a high number of undiagnosed cases live in the community. The potential impact of Mediterranean diet, hypertension control and decreasing vascular risk factors is discussed.
- Open Access
- 28 September 2010
- Published by Springer Nature in BMC Neurology
- Vol. 10 (1) , 87
Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment
Behavioural and psychological symptoms of dementia (BPSD) are non-cognitive symptoms commonly associated to Alzheimer's disease (AD). The characterization of the clinical profile of AD patients might help to better understand disease evolution and to improve diagnosis and treatment. Thus, the aim of the present study is to describe the clinical profile of AD patients, and to correlate the presence of BPSD with the severity of the disease.
- 28 September 2010
- Published by Springer Nature in BMC Neurology
- Vol. 10 (1) , 87
Open AccessBehavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment
Behavioural and psychological symptoms of dementia (BPSD) are non-cognitive symptoms commonly associated to Alzheimer's disease (AD). The characterization of the clinical profile of AD patients might help to better understand disease evolution and to improve diagnosis and treatment. Thus, the aim of the present study is to describe the clinical profile of AD patients, and to correlate the presence of BPSD with the severity of the disease.
- 1 September 2010
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 7 (6) , 517-526
Prevalence of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimers Disease, and its Relationship with Cognitive Impairment
Objective The study aimed to describe the prevalence of Neuropsychiatric symptoms (NPS) in Alzheimers disease (AD), amnestic mild cognitive impairment (MCI) and controls using the 12-item Neuropsychiatric Inventory (NPI) and to analyze the relationships between neuropsychiatric symptoms with specific neuropsychological tests.Patients and methods; We prospectively studied 485 patients from the Memory Unit in Cruces Hospital (Spain), 344 met the criteria of NINCDS-ADRDA for probable AD (99 were classified as mild and 245 as moderate-severe), 91 for MCI and 50 were controls. Mini-mental State Examination (MMSE) and CDR (Clinical Dementia Rating) were used to evaluate global cognitive function and to classify the severity of cognitive impairment. The neuropsychological test battery included memory test, verbal fluency, visuoespatial skills and daily living scales. The 12-items Neuropsychiatric Inventory (NPI) version was used to assess neuropsychiatric symptoms. All patients underwent a neuroimaging study (CT scan and/or MRI). Patients were not treated with antidementia or psychotropic drugs. Results;Apathy and depression were more prevalent NPS in moderate-severe AD (78.4% and 44.1%, respectively), mild AD (64.6% and 41.4%, respectively) and MCI (50.5% and 33%, respectively) patients than in controls (6% and 8%, respectively). The prevalence and the mean scores of all symptoms increased along the severity of the disease, except for sleep and appetite disorders. In patients with mild AD a relationship was found between the presence of NPS and RDRS-2 scale (p = 0.003); and between NPS and RDRS-2 (p = 0.029) and SS-IQCODE scales (p = 0.039) in moderate-severe patients.Conclusions; NPS were more prevalent in AD and MCI patients than in controls. In AD and MCI patients apathy and depression were the most prevalent NPS. The prevalence and the mean scores of all symptoms gradually increased along the severity of the disease, except for sleep and appetite disorders. We have no found a relationship between neuropsycological test and the presence of NPS, but in patients with mild and moderate-severe AD there is a relationship with daily living scales.
- 1 September 2010
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 7 (6) , 517-526
Prevalence of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimers Disease, and its Relationship with Cognitive Impairment
Objective The study aimed to describe the prevalence of Neuropsychiatric symptoms (NPS) in Alzheimers disease (AD), amnestic mild cognitive impairment (MCI) and controls using the 12-item Neuropsychiatric Inventory (NPI) and to analyze the relationships between neuropsychiatric symptoms with specific neuropsychological tests.Patients and methods; We prospectively studied 485 patients from the Memory Unit in Cruces Hospital (Spain), 344 met the criteria of NINCDS-ADRDA for probable AD (99 were classified as mild and 245 as moderate-severe), 91 for MCI and 50 were controls. Mini-mental State Examination (MMSE) and CDR (Clinical Dementia Rating) were used to evaluate global cognitive function and to classify the severity of cognitive impairment. The neuropsychological test battery included memory test, verbal fluency, visuoespatial skills and daily living scales. The 12-items Neuropsychiatric Inventory (NPI) version was used to assess neuropsychiatric symptoms. All patients underwent a neuroimaging study (CT scan and/or MRI). Patients were not treated with antidementia or psychotropic drugs. Results;Apathy and depression were more prevalent NPS in moderate-severe AD (78.4% and 44.1%, respectively), mild AD (64.6% and 41.4%, respectively) and MCI (50.5% and 33%, respectively) patients than in controls (6% and 8%, respectively). The prevalence and the mean scores of all symptoms increased along the severity of the disease, except for sleep and appetite disorders. In patients with mild AD a relationship was found between the presence of NPS and RDRS-2 scale (p = 0.003); and between NPS and RDRS-2 (p = 0.029) and SS-IQCODE scales (p = 0.039) in moderate-severe patients.Conclusions; NPS were more prevalent in AD and MCI patients than in controls. In AD and MCI patients apathy and depression were the most prevalent NPS. The prevalence and the mean scores of all symptoms gradually increased along the severity of the disease, except for sleep and appetite disorders. We have no found a relationship between neuropsycological test and the presence of NPS, but in patients with mild and moderate-severe AD there is a relationship with daily living scales.
- Open Access
- 19 October 2009
- Published by Springer Nature in BMC Neurology
- Vol. 9 (1) , 55
Prevalence of dementia and major dementia subtypes in Spanish populations: A reanalysis of dementia prevalence surveys, 1990-2008
This study describes the prevalence of dementia and major dementia subtypes in Spanish elderly. We identified screening surveys, both published and unpublished, in Spanish populations, which fulfilled specific quality criteria and targeted prevalence of dementia in populations aged 70 years and above. Surveys covering 13 geographically different populations were selected (prevalence period: 1990-2008). Authors of original surveys provided methodological details of their studies through a systematic questionnaire and also raw age-specific data. Prevalence data were compared using direct adjustment and logistic regression. The reanalyzed study population (aged 70 year and above) was composed of Central and North-Eastern Spanish sub-populations obtained from 9 surveys and totaled 12,232 persons and 1,194 cases of dementia (707 of Alzheimer's disease, 238 of vascular dementia). Results showed high variation in age- and sex-specific prevalence across studies. The reanalyzed prevalence of dementia was significantly higher in women; increased with age, particularly for Alzheimer's disease; and displayed a significant geographical variation among men. Prevalence was lowest in surveys reporting participation below 85%, studies referred to urban-mixed populations and populations diagnosed by psychiatrists. Prevalence of dementia and Alzheimer's disease in Central and North-Eastern Spain is higher in females, increases with age, and displays considerable geographic variation that may be method-related. People suffering from dementia and Alzheimer's disease in Spain may approach 600,000 and 400,000 respectively. However, existing studies may not be completely appropriate to infer prevalence of dementia and its subtypes in Spain until surveys in Southern Spain are conducted.
- 19 October 2009
- Published by Springer Nature in BMC Neurology
- Vol. 9 (1) , 55
Open AccessPrevalence of dementia and major dementia subtypes in Spanish populations: A reanalysis of dementia prevalence surveys, 1990-2008
This study describes the prevalence of dementia and major dementia subtypes in Spanish elderly. We identified screening surveys, both published and unpublished, in Spanish populations, which fulfilled specific quality criteria and targeted prevalence of dementia in populations aged 70 years and above. Surveys covering 13 geographically different populations were selected (prevalence period: 1990-2008). Authors of original surveys provided methodological details of their studies through a systematic questionnaire and also raw age-specific data. Prevalence data were compared using direct adjustment and logistic regression. The reanalyzed study population (aged 70 year and above) was composed of Central and North-Eastern Spanish sub-populations obtained from 9 surveys and totaled 12,232 persons and 1,194 cases of dementia (707 of Alzheimer's disease, 238 of vascular dementia). Results showed high variation in age- and sex-specific prevalence across studies. The reanalyzed prevalence of dementia was significantly higher in women; increased with age, particularly for Alzheimer's disease; and displayed a significant geographical variation among men. Prevalence was lowest in surveys reporting participation below 85%, studies referred to urban-mixed populations and populations diagnosed by psychiatrists. Prevalence of dementia and Alzheimer's disease in Central and North-Eastern Spain is higher in females, increases with age, and displays considerable geographic variation that may be method-related. People suffering from dementia and Alzheimer's disease in Spain may approach 600,000 and 400,000 respectively. However, existing studies may not be completely appropriate to infer prevalence of dementia and its subtypes in Spain until surveys in Southern Spain are conducted.
- Open Access
- 30 September 2009
- Published by Springer Nature in BMC Neuroscience
- Vol. 10 (1) , 125
The COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers
The aim of this study is to examine the influence of the catechol-O-methyltranferase (COMT) gene (polymorphism Val158 Met) as a risk factor for Alzheimer's disease (AD) and mild cognitive impairment of amnesic type (MCI), and its synergistic effect with the apolipoprotein E gene (APOE).
- 30 September 2009
- Published by Springer Nature in BMC Neuroscience
- Vol. 10 (1) , 125
Open AccessThe COMT Val158 Met polymorphism as an associated risk factor for Alzheimer disease and mild cognitive impairment in APOE 4 carriers
The aim of this study is to examine the influence of the catechol-O-methyltranferase (COMT) gene (polymorphism Val158 Met) as a risk factor for Alzheimer's disease (AD) and mild cognitive impairment of amnesic type (MCI), and its synergistic effect with the apolipoprotein E gene (APOE).
- Open Access
- 15 October 2008
- Published by Springer Nature in BMC Neurology
- Vol. 8 (1) , 39
Risk factors for dementia in the epidemiological study of Munguialde County (Basque Country-Spain)
Prevalence of degenerative dementias and dementias associated with cerebrovascular disease is increasing. Dementia is one of the most significant public health problem. In recent years, the role of vascular risk factors (hypertension, diabetes mellitus and hypercholesterolemia) and depression has been evaluated.
- 15 October 2008
- Published by Springer Nature in BMC Neurology
- Vol. 8 (1) , 39
Open AccessRisk factors for dementia in the epidemiological study of Munguialde County (Basque Country-Spain)
Prevalence of degenerative dementias and dementias associated with cerebrovascular disease is increasing. Dementia is one of the most significant public health problem. In recent years, the role of vascular risk factors (hypertension, diabetes mellitus and hypercholesterolemia) and depression has been evaluated.